An open-label, randomized, phase 2 study of efficacy and tolerability of ABT-869 in advanced or metastatic non-small cell lung cancer (NSCLC).

Trial Profile

An open-label, randomized, phase 2 study of efficacy and tolerability of ABT-869 in advanced or metastatic non-small cell lung cancer (NSCLC).

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Linifanib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 03 Aug 2012 Additional lead trial investigator (Ricker J) added as reported by ClinicalTrials.gov.
    • 29 Dec 2011 Planned End Date changed from 1 Dec 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
    • 19 Jul 2011 Planned End Date changed from 1 Jun 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top